Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors


Available for licensing are novel pyrrolopyrimidine compounds that disrupt the assembly of the perinucleolar compartment (PNC), a sub-nuclear structure highly prevalent in metastatic tumors. These notable compounds act without overt cytotoxicity.

The presence of the PNC positively correlates with metastatic capacity, making it a potential marker for cancer development and prognosis. These compounds could also serve as useful tools to elucidate the biology driving the formation and maintenance of the PNC, and unravel its association with metastasis.

Potential Commercial Applications: Competitive Advantages:
  • Use in the therapeutic intervention of metastasis in cancer
  • Use as tools to elucidate the biology of the PNC
 
  • No existing FDA-approved treatment for the clinical management of metastasis
  • Target is specific to metastatic tumors
  • Compounds are not toxic
  • Broadly acting across all metastatic cancers


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

Samarjit Patnaik (NCATS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,663,521 issued 2017-05-30
U.S. Pat: 10,301,314 issued 2019-05-28
US Application No. 14/364,759
US Application No. 15/606,740

Collaboration Opportunity:

The National Center for Advancing Translational Sciences is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact the NCATS Office of Strategic Alliances at NCATSPartnerships@mail.nih.gov.


Licensing Contact:
Suryanarayana Vepa, Ph.D.
Email: sury.vepa@nih.gov
Phone: 301-827-7181

OTT Reference No: E-276-2011-0
Updated: Apr 21, 2016